Adam 33 20 mg (Tablet)

Indications

• Rheumatic Disorders
• Endocrine Disorders
• Dermatologic Diseases
• Allergic States
• Respiratory Diseases
• Hematologic Disorders
• Edematous States
• Gastrointestinal Diseases

Pharmacology

• Glucocorticoid Properties
• Inhibition of Phospholipase A2 Enzyme
• Metabolism in Liver
• Urinary Excretion

Dosage & Administration

• Adult Nephrotic Syndrome Dose
• Adult Anti-inflammatory Dose
• Adult Acute Asthma Dose
• Adult Allergic Conditions Dose
• Pediatric Asthma Dose
• Pediatric Anti-inflammatory Dose
• Pediatric Immunosuppression Dose

Interaction

• Reduced Efficacy with Aminoglutethimide
• Reduced Efficacy with Antacids
• Reduced Efficacy with Barbiturates
• Reduced Efficacy with Carbamazepine
• Reduced Efficacy with Griseofulvin
• Reduced Efficacy with Mitotane
• Reduced Efficacy with Phenylbutazone
• Reduced Efficacy with Phenytoin
• Reduced Efficacy with Primidone
• Reduced Efficacy with Rifampin

Contraindications

• Systemic Infections
• Hypersensitivity
• Ocular Herpes Simplex

Side Effects

• Increased Appetite
• Indigestion
• Nervousness or Restlessness
• Skin Color Changes
• Dizziness or Lightheadedness
• Flushing of Face or Cheeks
• Hiccups
• Increased Sweating
• Sensation of Spinning

Pregnancy & Lactation

• Not Recommended During Pregnancy
• Breast Milk Presence

Precautions & Warnings

• Diabetes
• Hypertension
• Psychological Disturbances
• Osteoporosis
• Post-menopausal Women
• Chronic Nephritis
• Long-term Use Caution

Overdose Effects

• Adverse Effects Development
• Gradual Dose Reduction

Therapeutic Class

• Glucocorticoids

Storage Conditions

• Cool and Dry Storage
• Protected from Light
• Keep Out of Reach of Children

Related Brands

• Adam 33 5 mg (Tablet) - nuvista-pharma-ltd